Can Melanoma Spread To The Brain

Predictive Factors For Overall Survival

We analyzed the potential association between several factors and survival using univariate Cox regression of overall survival . Intriguingly, of factors in the primary tumor, increased levels of tumor-infiltrating lymphocytes showed a trend toward improved survival in patients with brain metastasis. Several clinical factors were found to be significantly associated with overall survival in patients with brain metastasis by univariate analysis . Factors associated with shorter overall survival included male sex, cerebellar involvement, higher number of metastatic brain tumors, concurrent presence of adrenal metastasis, or treatment with whole-brain radiation therapy. Factors associated with longer overall survival were treatment with craniotomy, stereotactic radiosurgery, or anti-PD-1 antibody therapy after initial diagnosis of brain metastasis.

Table 4 Univariate Cox regression analysis of association of various clinical factors with overall survival in melanoma patients with brain metastasis

Multivariate analysis of all eight factors revealed cerebellar involvement, craniotomy, and adrenal involvement as independently predictive of survival . There was trend toward significance for treatment with anti-PD-1 antibody .

Table 5 Multivariate Cox regression analysis of association of various clinical factors with overall survival in melanoma patients with brain metastasis

Survival And Clinical Outcome

Fifty-nine patients had died of melanoma progression at the time of the analysis, among which 32 died with progressing brain metastases. The median overall survival duration from the time of initial brain metastasis was 12.8 months , and the median overall survival duration from the time of initial melanoma diagnosis was 60.5 months for all 79 patients. The median overall survival durations from the time of craniotomy and stereotactic radiosurgery were 17.3 months and 15.4 months , respectively. The median survival durations of patients who received anti-CTLA-4 antibody, anti-PD-1 antibody and BRAF inhibitor after the diagnosis of brain metastasis were 19.2 months , 37.9 months and 12.7 months , respectively. Tables and describe the outcomes of the entire cohort as well as specific subsets of patients. Figures and illustrate the Kaplan-Meier curves of overall survival for all patients and for those who were treated with or without anti-PD-1 therapy, respectively.

Fig. 1

Comparing Metastatic Melanoma Cells In Lymph Versus Blood

Most studies of cancer cell metastasis in people have focused on cells circulating in the blood. Thats because its much easier to collect patient blood samples than it is to collect samples of lymph, the clear fluid that carries immune cells through vessels of the lymphatic system, Dr. Morrison said.

Dr. Morrisons team found that human melanoma cells injected into lymph nodes in the mice were more likely to form distant tumors than melanoma cells injected into blood.

To study the role of lymph in metastasis, lead investigator Jessalyn Ubellacker, Ph.D., a postdoctoral researcher in Dr. Morrisons lab, figured out how to collect melanoma cells from lymph in mice. This allowed the team to do the first side-by-side comparison of melanoma cells spreading through lymph and through blood in the same animal, Dr. Morrison said.

Next the team found that melanoma cells in lymph experienced less oxidative stress than melanoma cells in blood. That offered a potential explanation for why melanoma cells from lymph nodes were surviving better and better able to form a tumor, Dr. Morrison said.

Further experiments showed that melanoma cells in blood are vulnerable to ferroptosisa form of cell death that occurs when lipids damaged by oxidative stress build up in the outer membrane of a cell. By contrast, melanoma cells from lymph nodes were protected from ferroptosis.

Recommended Reading: Invasive Ductal Carcinoma Grade 3 Life Expectancy

Lymph Nodes As A Stopover On A Cancer Cells Journey

Movement of melanoma cells into lymph nodes is not necessarily an endpoint, but rather a stopover on the cells journey elsewhere, wrote Barbara Grüner, Ph.D., of University Hospital Essen in Germany, and Sarah-Maria Fendt, Ph.D., of the Leuven Center for Cancer Biology in Belgium, in .

These results provide a first step towards understanding the protective environment of lymph, Drs. Grüner and Fendt wrote. To what extent findings apply to tumor types other than melanoma, and to humans, remains to be determined. If the results are relevant to human disease, innovative ways must be found for them to have a therapeutic impact.

Dr. Morrisons team is already looking into existing drugs that might make cancer cells more vulnerable to ferroptosis and block the protective effects of lymph, he said. The idea would be to see if such a drug could be given early in the disease course of melanoma to prevent it from spreading.

If we can find a therapy that blocks disease progression in mice, then we would go into clinical trials to see if it works in humans, he added.

Dr. Salnikow said multiple approaches will likely be needed to prevent the spread of melanoma, because different biological factors may be important for metastasis in different people.

One of the interesting questions to answer is whether MCT1 is also helping to protect these melanoma cells metastasizing through lymph, and were doing those experiments now, Dr. Morrison said.

What If I Have Metastatic Melanoma Symptoms

Whether you have a suspicious mole or are experiencing some symptoms of advanced-stage melanoma, it is important to consult with a physician to receive an accurate diagnosis, as many other conditions can cause similar symptoms. At Moffitt Cancer Center, we provide a comprehensive range of screening, diagnostic, treatment and supportive care services for patients with melanoma and other types of cancer. Within our Cutaneous Oncology Program, our multispecialty team includes surgeons, dermatologists, medical oncologists and other experts who work together as a tumor board to ensure our patients receive the best possible treatment and care.

If you would like to schedule an appointment at Moffitt to discuss your metastatic melanoma symptoms, call or fill out a new patient registration form online. We do not require a referral to schedule an appointment.

• BROWSE

Read Also: Clear Cell Carcinoma Symptoms

Metastatic Melanoma In The Brain

Brain metastases can cause neurological problems such as seizures, dizziness, and vision and hearing problems. Although current therapies used to treat brain metastases may help to alleviate these symptoms, they can also compromise brain function. According to a 2010 study, only 5% of people with melanoma that has spread to the brain will live more than 5 years after a diagnosis of brain metastases.

With the availability of new immunotherapies over the past few years, though, the survival rate may be changing, Dr. Sharon said.

A handful of small studies provided initial evidence that, on their own or in combination, ipilimumab and nivolumab may shrink melanoma brain metastases. The new phase 2 trialsponsored by Bristol-Myers Squibb, the manufacturer of nivolumab and ipilimumabwas launched to provide stronger evidence.

More than 100 people with at least one metastatic melanoma tumor in the brain were enrolled in the trial. People with certain conditions or medical histories were excluded, such as those with cancer in part of the brain called the leptomeninges, with neurological symptoms from brain metastases, or who had been treated with steroids to alleviate swelling in the brain.

Case Reportmetastatic Malignant Melanoma Of Unknown Primary Site To The Brain: A Case Report

Aggressive tumor whose pathogenesis is poorly understood.

Presents metastatically without an identifiable primary lesion.

Treatment guidelines for these patients are not clear-cut.

Poor outcome despite various local and systemic therapies.

Promising new agents and approaches are needed

Recommended Reading: Malignant Breast Cancer Survival Rate

What Is Brain Metastases

Brain metastases, a specific form of Stage IV melanoma, are one of the most common and difficult-to-treat complications of melanoma. Brain metastases differ from all other metastases in terms of risk factors, diagnosis, and treatment.

Until recently, melanoma brain metastases carried a poor prognosis, with a median overall survival of about four to five months, but improvements in radiation and systemic therapies are offering promise for this challenging complication, and some patients are curable. Historically, people with a single brain metastasis who undergo effective treatment have a better chance for long-term survival than do people with multiple metastatic tumors.

How Can Melanoma Spread To The Brain

While melanoma normally begins in the skin, cancer cells sometimes grow and break away from the place where the cancer began. The cells that break away often travel to nearby:

• Blood vessels

• Lymph nodes

Once in the blood or lymph , the melanoma cells often travel to the lungs, liver, spleen, or brain.

Cancer cells growing bigger than normal cells

Cancer cells can grow, break off, and spread.

Also Check: Cancer All Over Body Symptoms

Metastatic Brain Cancer Prognosis

Prognosis for metastatic brain cancer varies greatly. Keep in mind that each patient is unique, and with newer treatments, many patients live longer. Speaking with your care team about your unique diagnosis can provide an accurate prognosis.

Palliative Care at Johns Hopkins

Palliative care is specialized medical care that helps patients facing serious illnesses and their families by adding an extra layer of support.

Palliative care teams can help with the symptoms and the stress of living with a serious illness, including controlling pain, providing support for the mental and emotional effects of an illness, and managing other symptoms.

Research Shows Deadly Tumors May Be Vulnerable To Drugs That Block Their Energy Supply

Date:

University of Texas M. D. Anderson Cancer Center

Summary:

Melanoma tumors that have spread to the brain are equipped to thwart immunotherapies and targeted therapies that succeed against tumors growing in other sites. Researchers report that the heavy reliance of these tumors on a specific metabolic pathway presents a potentially new therapeutic against these lethal tumors.

Melanoma tumors that have spread to the brain are equipped to thwart immunotherapies and targeted therapies that succeed against tumors growing in other sites. Researchers at The University of Texas MD Anderson Cancer Center report in Cancer Discovery that the heavy reliance of these tumors on a specific metabolic pathway presents a potentially new therapeutic against these lethal tumors.

The team’s in-depth analysis of brain metastases and comparison of those tumors to others that had spread to different parts of the body was the first such application of advanced RNA sequencing and uncovered a variety of factors that make tumors in the brain so difficult to treat.

“Brain metastases are increasingly recognized as one of our biggest challenges in cancer,” said senior author Michael Davies, M.D., Ph.D., associate professor of Melanoma Medical Oncology. “Melanoma patients with advanced disease have the highest risk of developing brain metastases among common solid tumors, and they are a leading cause of death from this disease.”

Beyond the blood-brain barrier

OXPHOS metabolism matters

Read Also: Does Amelanotic Melanoma Blanch When Pressed

What Determines The Treatment Options And Prognosis For Patients With Brain Metastases

Certain characteristics of both the patient and the cancer will affect the patients prognosis as well as eligibility for treatment. The following factors are associated with better outcomes :

• Younger age: less than 60 years old
• Fewer vs. more brain metastases: fewer than three lesions
• No extracranial disease
• Normal LDH
• Highgreater than 70Karnofsky Performance Status score

What Is Metastatic Melanoma

Metastatic melanoma occurs when the cancerous cells from the original tumor get loose, travel through the lymph or blood circulation, and start a new tumor somewhere else. Once it spreads, or metastasizes, the disease is known as metastatic melanoma. This type of melanoma may typically occur during stage III or stage IV. Common sites for metastases include the lymph nodes, lungs, liver, bones and brain.

About 106,110 adults in the United States will be diagnosed with melanoma in 2021, according to the American Society of Clinical Oncology . Approximately 4 percent of people are diagnosed with melanomas that have spread to distant parts of the body, according to the ASCO. This is the most advanced stage of metastatic melanoma.

The percentage of people diagnosed with melanoma that has spread to nearby lymph nodes is 8.5 percent, according to the National Cancer Institute . These cases have a slightly better prognosis.

From 2014 to 2018, the incidence rate of melanoma that had spread to distant parts of the body was 0.9 per 100,000 people, according to the NCI.

Melanoma tumors that have metastasized to other parts of the body are still considered melanoma. For example, melanoma found in the lungs is called metastatic melanoma of the lung or melanoma with lung metastases.

Don’t Miss: How Do Carcinomas Spread

Who Is At Risk

More than 60% of all Stage IV melanoma patients will develop brain metastases at some point, but certain factors increase the risk :

• The primary tumor was on the head, neck, trunk, or abdomen
• The primary tumor was ulcerated, deep, or invasive
• The LDH is elevated at diagnosis of unresectable Stage III or Stage IV
• The presence of NRAS or BRAF mutation
• The melanoma has spread to the internal organs

Drug Combo Fights Melanoma That’s Spread To Brain

HealthDay Reporter

THURSDAY, Aug. 23, 2018 — A combination of two drugs that work with the immune system can help beat back melanoma that has moved to the brain, an early clinical trial has found.

The study included 94 patients with advanced melanoma that had invaded the brain. All were treated with two “immunotherapy” drugs — Opdivo and Yervoy — which help the immune system find and destroy tumors.

Overall, 57 percent of the patients saw their brain tumors disappear, shrink or remain stable for at least six months. For most, the responses were still evident at their latest follow-up, at the 14-month mark.

And after one year, more than 80 percent of all patients were still alive.

“That’s really tremendous,” said lead researcher Dr. Hussein Tawbi, of the University of Texas M.D. Anderson Cancer Center in Houston. “Without treatment, that rate would be about 20 percent.”

Experts said the findings represent another step forward against advanced melanoma, the deadliest form of skin cancer. Once melanoma spreads to distant sites in the body, the prognosis has traditionally been grim. When it infiltrates the brain, the typical life expectancy has hovered around four to five months, according to Tawbi.

But in recent years, several new drugs have been approved to fight advanced melanoma. They include Opdivo and Yervoy, which are already used in combination.

But major trials of the drugs, Tawbi said, have excluded patients with brain metastases .

Show Sources

You May Like: What Is The Prognosis For Basal Cell Carcinoma

What Is A Brain Metastasis

Metastatic brain tumors begin as cancer in another part of the body and spread to the brain through the blood stream. There can be one tumor or multiple tumors . The most common cancers that spread to the brain are lung , breast , skin melanoma , kidney and colon . A metastatic brain tumor may also be referred to as a secondary tumor. When a skin cancer metastasizes to the brain, this “brain tumor” is actually a mass of skin cancer cells .

Some brain metastases appear years after the primary cancer. Others metastasize so quickly that they are discovered before the primary cancer. If the primary cancer cannot be found, it is called an unknown primary. A diagnostic work-up with imaging scans may be done to look for the primary cancer site. Treatment options vary depending on the location and number of brain lesions along with the location and severity of the primary cancer.

The 4 Stages Of Melanoma

Two main things determine the stage of melanoma: The thickness or depth of the tumor and how far it has spread when its diagnosed, explains David Polsky, M.D., dermatologist at NYU Langone Medical Center in New York City. In stages 0, 1, and 2, the melanoma is limited to the skin. In stage 3, its spread to the lymph nodes, small structures throughout your body that help filter fluids and fight infection. In the most advanced stage, stage 4, melanoma cells have broken away from the original tumor, traveled through the body and formed a new tumor somewhere else.

Recommended Reading: What Is The Survival Rate For Invasive Lobular Carcinoma

The Spread Of Melanoma Metastasis

• Can Metastasis be Prevented?

If you or a family member or friend have recently been diagnosed with melanoma, you may be wondering, just where and why can melanoma spread?

With surgery, melanoma confined to the skin has a 5-year survival rate in 98% of cases. Unfortunately, if the lesion recurs , gets thicker, or spreads from the skin to the lymph nodes or distant organs, it becomes much more dangerous. This occurs in stage III and IV melanoma and is called melanoma metastasis.

How Is Skin Cancer Of The Head And Neck Diagnosed

Diagnosis is made by clinical exam and a biopsy. Basal cell and squamous cell cancers are staged by size and extent of growth. Basal cell cancers rarely metastasize to lymph nodes, but they can grow quite large and invade local structures. Squamous cell cancers have a much higher incidence of lymph node involvement in the neck and parotid gland and can spread along nerves.

Melanoma is staged, based not on size but on how deeply it invades the skin layers. Therefore, a superficial or shave biopsy will not provide accurate staging information used to guide treatment. Melanomas can have a very unpredictable course and may spread to distant organs. Melanomas with intermediate thickness often require sentinel node biopsy, a surgical procedure performed by a head and neck surgeon, to determine if microscopic spreading to lymph nodes has occurred.

Read Also: Invasive Ductal Carcinoma Survival Rate Stage 4

Diagnosis And Treatment Options For Brain Metastasis Of Melanoma

Submitted: November 8th 2010Reviewed: April 26th 2011Published: October 5th 2011

DOI: 10.5772/20382

• Johns Hopkins University School of Medicine, Department of Neurosurgery, Baltimore,, USA

*Address all correspondence to: